November 28, 2024 - 08:51

In a significant move, former President Donald Trump has selected a Stanford University professor known for his critical stance on COVID-19 lockdowns to lead a key health agency. This appointment comes as part of Trump’s ongoing efforts to reshape health policy and address public health challenges in the wake of the pandemic. The professor, who has gained attention for advocating against strict lockdown measures, is expected to bring a controversial perspective to the role.
Before officially assuming the position, the appointee will need to secure confirmation from the U.S. Senate, a process that could spark intense debate given the professor's previous comments and the current political climate surrounding public health policies. Trump's choice reflects his commitment to appointing individuals who align with his views on government intervention and public health measures. As the nation continues to navigate the complexities of health care and pandemic response, this appointment is poised to influence future strategies and discussions within the health sector.
May 9, 2026 - 22:43
College of Pharmacy & Health Sciences confers 206 degrees - NewsThe Campbell University College of Pharmacy & Health Sciences held its spring commencement ceremony to honor the achievements of the Class of 2026. A total of 206 degrees were conferred during the...
May 9, 2026 - 02:40
California Becomes First State to Offer Free Diapers for Every NewbornCalifornia is set to launch a first-of-its-kind program that will provide free diapers to every newborn in the state. The initiative, which makes California the first state in the country to offer...
May 8, 2026 - 11:45
Maryland ranked high among states for public health preparedness, but could be doing moreMaryland continues to rank among the top states in the nation for its ability to handle public health emergencies, according to a recent analysis by a national health policy organization. The state...
May 7, 2026 - 18:47
Healthy Returns: First Ozempic generics in Canada will be a test case for Novo NordiskThe arrival of the first generic versions of semaglutide in Canada is being watched closely as a potential turning point for Novo Nordisk`s dominance in the global weight-loss and diabetes market....